BioSpace News Archive

Biocept, Inc announces that COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant.

After nearly a year in intensive care at Children’s Hospital of Philadelphia, 10-month-old conjoined twins Addison and Lilianna Altobelli were successfully separated by CHOP surgeons on October 13, 2021.

Medivir AB (Nasdaq Stockholm: MVIR-B) today announces that an e-poster entitled “Liver biopsy biomarkers in a phase 1 study of the prodrug MIV-818 demonstrates proof-of-concept for cancer in the liver” will be presented at the European Association for the Study of the Liver (EASL) Liver Cancer Summit 3-4 February.

ELEVAI LABS, INC. is pleased to announce that it has signed a non-exclusive global distributor and trademark license agreement with leading Australian headquartered aesthetic device company DermapenWorld™ (“Dermapen”).

Nicox SA, an international ophthalmology company, provided business and financial highlights for fourth quarter 2021 for Nicox SA and its subsidiaries as well as key expected value-inflection milestones.

United Therapeutics Corporation, a public benefit corporation with a purpose to provide a brighter future for patients, announced that the world’s first recipient of an investigational genetically-modified xenotransplanted organ, UT’s UHeart™, reached a two-week milestone.

The Board of Directors of Sensient Technologies Corporation has declared a regular quarterly cash dividend on its common stock of $0.41 per share.

Orchard Therapeutics today announced the publication in The Lancet of long-term clinical outcomes evaluating the safety and efficacy of Libmeldy® (atidarsagene autotemcel) for the treatment of early-onset metachromatic leukodystrophy (MLD).

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present virtually at the B. Riley Securities Oncology Investor Conference.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, met all secondary endpoints measured at 18 months in patients with hATTR amyloidosis with polyneuropathy.